For the founders of Horus Pharma, Martine and Claude Claret, growth is based on the international expansion of the group, in order to extend the influence of innovation :
International expansion is becoming a key business objective. Though the laboratory’s international expansion began in 2010 in Western Europe, today it takes on a new dimension with the signing of distribution agreements in Eastern Europe and across the Atlantic. .
2015 marks another key milestone for Horus Pharma with the launch of first European subsidiaries.
2017 marks the opening of the third subsidiary with the Netherlands.
Though our eye is on the international market, the foundations of Horus Pharma remain firmly anchored in France, where the laboratory has built a strong national network bringing together research sites, academic structures, health institutions, patient associations and manufacturing sites in subcontracting. With over 60% of its annual production units carried out in France, Horus Pharma remains true to its values and its roots, valuing the expertise and local know-how above all, to help bring them together and to offer them international exposure.
